Regeneron Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 68 to 71 before the market opened Wednesday -- a welcome improvement, but still short of the 80 or better score you prefer to see. Was this the cause of the small gap up at the open?
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research shows that the top-performing stocks often have an 80 or higher RS Rating as they begin their largest runs. See if Regeneron Pharmaceuticals can continue to rebound and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
Regeneron Pharmaceuticals is building a flat base with an 853.97 buy point. After a strong open, it continued to increase the stock price, although volume is trending lower than the average. See if it can clear the breakout price in heavier trading.
REGN Earnings
Earnings-per-share growth decreased in the company's latest report from 5% to 4%, but sales rose from 11% to 15%.
Regeneron Pharmaceuticals earns the No. 10 rank among its peers in the Medical-Biomed/Biotech industry group. Immunogen and Neurocrine Biosciences are also among the group's highest-rated stocks.
